ICLE 2022 | Developing autologous T-cell therapies with CRISPR-Cas technology
Mateusz Legut
• 31 Mar 2022
Mateusz Legut, PhD, New York Genome Center, New York, NY, discusses hurdles associated with utilizing Crispr-Cas9 in engineering autologous T-cell therapies. Whilst the technology has led to successful knockout of numerous T-cell receptors in the context of developing cell therapies, inefficient editing, chromosomal aberrations and off-targets are major pitfalls in using Crispr-Cas9. Dr Legut also talks on optimizing T-cell therapies by screening the genome for novel genes via lentiviral vector-mediated overexpression. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
